Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2018 Q2- Text added to 2018 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. senior Avg
|
New words:
begun, Bellina, Comparison, fluorocytosine, Frank, IBC, Jordan, Matthew, McLinn, Mongiello, permission, proportionately, tan, television, Trickett, unconstrained, Wendler, Wholesale
Removed:
alipogene, Amgen, axicabtagene, ciloleucel, conversion, deterioration, distantly, flucytosine, Fondazione, GlaxoSmithKline, Glybera, Imlygic, improve, issuable, Kite, Kymriah, laherparapvec, melanoma, NV, Ospedale, Pharma, RAC, Raffaele, regionally, remaining, San, scheduled, talimogene, Telethon, tiparvovec, tisagenlecleucel, uniQure, unresectable, widely, Yescarta
Valuein 2018 Q2 filing- Value in 2018 Q3 filing
Original filings
Filing view